最新ニュース Eli Lilly (NYSE:LLY) 株価情報

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

News

Upgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

HOOD

TTWO

主要なアナリストが株式レーティングを見直したトピックスを紹介する。アナリストのレーティング変更（格上げ・格下げを含む）はアナリストレーティングのページをご覧いただきたい。

ロビンフッドのアナリスト　市場への評価を変更

Equities

Markets

ASTS

DXCM

TSLA

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。

米国株式市場　テスラが市場を牽引　NBA契約でディズニーも上昇

Short Sellers

Short Ideas

Eli Lilly and Co (NYSE:LLY) のフロートに対する新しいショート比率は、前回の報告から14.06％上昇しています。同社は最近、ショートで売られた株は616万株あり、これは取引可能なすべての普通株の0.73％に相当します。平均してこの株のショートポジションをカバーするには、トレーダーは2.39日かかります。

イーライリリー社をショート比率から分析

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

President Joe Biden prioritized <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">freeing non-violent drug offenders</a> during his final few days in the White House, but TikTok? That's President-elect Donald Trump's problem now. 
According to the <a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">Associated Press</a>, Biden has no intention of enforcing the ban, which takes effect on his last full day in office, Jan. 19, and one day <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">before Trump&#8217;s inauguration</a>.
With a deadline looming, the app's fate lands in the hands of the so-called People's Bid for TikTok—backed by none other than Kevin O'Leary of &#8220;Shark Tank&#8221; and billionaire Frank McCourt. Apparently, TikTok's U.S. assets are still up for grabs, but no word yet on the price tag or whether a deal can realistically get done <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">in a few days</a>.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Joann Inc. is stitching together a bankruptcy plan for the second time within 12 months. The Ohio-based fabric and crafts retailer is seeking a buyer for its portfolio of some 800 stores. 
Gordon Brothers Retail Partners emerged as the &#8220;stalking horse&#8221; bidder, but Joann remains hopeful for better offers—perhaps from someone who knows how to thread the needle.
Previously, the 82-year-old retailer was under the stewardship of private equity firm Leonard Green &amp; Partners, which acquired it via a $1.6 billion leveraged buyout in 2011. The firm buried the company under a pile of debt (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">reportedly</a> $921 million in long-term debt as of Oct. 31, 2020) and <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">sent it public in 2021</a>. 
Joann went private again in <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">March</a> 2024 while under Chapter 11 bankruptcy protection. The company managed to reduce its $1 billion total debt by about $500 million at the time.
Despite efforts to save itself last year, Joann is joining the growing quilt of recent retail casualties: Party City, Big Lots, LL Flooring, The Body Shop and The Container Store <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">to name a few</a>.
Kirkland &amp; Ellis is handling legal matters, while Centerview Partners LLC offers financial advice. Alvarez &amp; Marsal North America, LLC is overseeing the restructuring process.
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Investment firm KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) hired Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to run an auction for its minority stake in Philippine fintech company Maya, Reuters reported. </li>
<li>New York-headquartered KKR owns more than 20% of Maya and the potential sale, if it goes through, could value Maya at more than $2 billion, one of the sources said.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is looking to <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">jettison its electronics business</a>. The Wilmington, Delaware-based company expects the transaction to be completed by Nov. 1. DuPont also decided to retain its water business after evaluating strategic alternatives.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is shopping its Performance Chemicals Industrial Specialties segment, which includes divesting parts of its North Charleston, South Carolina site. The company hopes to improve earnings cash flow and conclude the review process by year-end. Whether a transaction comes about <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">remains to be seen</a>. </li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is up for sale. It&#8217;s also considering a merger or recapitalization as part of a larger strategic review. The Longmont, Colorado-based company has already sold its Australia subsidiary. &#8220;We continue to support all initiatives that optimize shareholder value and will consider the full range of potential strategic alternatives to ensure S&amp;W Seed is best positioned for future success,&#8221; chairman Alan Willits said.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">Starship Explodes During Flight Test, Elon Musk Says: &#8216;Success Is Uncertain, But Entertainment Is Guaranteed!&#8217;</a>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Lourenco Goncalves raised eyebrows during a Monday press conference. According to <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">Bloomberg</a>, the CEO of Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) called Japan, a U.S. ally, &#8220;evil&#8221; and accused it of teaching China harmful practices like dumping and overproduction. His comments came as Cleveland-Cliffs eyes a new bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), following Biden&#8217;s decision to block Nippon Steel&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$14 billion acquisition attempt</a>. While positioning his company as a potential buyer, Goncalves&#8217; rhetoric escalated tensions within the steel industry. Nippon is now looking to Trump to <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">help close the deal</a>. </li>
<li>T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) will buy Vistar Media for $600 million. The telecom company expects the deal to strengthen its advertising business, Reuters reported. </li>
</ul>
Deals in the biotech and pharmaceutical sectors piled up this week. Here&#8217;s a sample of Benzinga&#8217;s coverage:
<ul>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already own <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">for $7.22 per share</a>. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">agreed to acquire</a> IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. The deal may require an additional $150 million from GSK after certain regulatory approval milestones. </li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) scooped up Scorpion Therapeutics&#8217; early-stage <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">cancer program for $2.5 billion</a>. </li>
<li>Like Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is seeking to bolster its neuropsychiatric portfolio<a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal"> with a $15 billion deal</a></li>
<li>Crown Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) offered to acquire all outstanding common shares of Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at $3.10 per share.</li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) agreed to a deal with Decoy Therapeutics, a preclinical biotech focused on peptide conjugate therapeutics. The merged entity will target unmet needs in respiratory diseases and GI oncology.</li>
<li>Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) strengthens its radiopharmaceutical position with<a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging"> $350 million acquisition of Life Molecular Imaging</a>.</li>
</ul>
For last week&#8217;s edition of Deal Dispatch, <a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">Eccentric Billionaire, Legendary Filmmaker Howard Hughes&#8217; Former Miami Estate On Market For $55.5 Million</a></li>
</ul>
Image created with a photo from Shutterstock.

ABBV

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has risen 5.88% since its last report. The company recently reported that it has 6.10 million shares sold short, which is 0.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737141312_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 4.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Eli Lilly?

<a href="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html" title="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html">https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html</a>

AMGN

TEVA

'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC

On Wednesday, the FDA approved Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;Omvoh&nbsp;(mirikizumab-mrkz) for moderately to severely active Crohn&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43015170/fda-approves-lillys-omvoh-mirikizumab-mrkz-for-crohns-disease-expanding-its-use-to-the-second-majo" rel="noreferrer noopener">disease in adults</a>.
Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its&nbsp;October 2023&nbsp;approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43013223/eli-lilly-adjusts-outlook-ceo-david-ricks-explains-revenue-shortfall" rel="noreferrer noopener">Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall</a>
Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.
Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn&#8217;s disease at the time of approval.
The approval is based on results from the Phase 3 VIVID-1 study. Patients randomized to placebo who did not achieve clinical response by patient-reported outcome at 12 weeks (40% of placebo patients) were subsequently switched to Omvoh treatment. Both primary endpoints in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41314649/more-patients-on-eli-lillys-mirikizumab-achieved-histologic-response-at-one-year-compared-to-john" rel="noreferrer noopener">VIVID-1 were achieved</a>:
<ul>
<li>Clinical remission by Crohn&#8217;s Disease Activity Index (CDAI) at one year53% of patients treated with Omvoh achieved clinical remission at one year versus 36% on placebo.</li>
<li>Endoscopic response at one year46% of patients treated with Omvoh had visible healing of the intestinal lining at one year versus 23% on placebo.</li>
</ul>
Additionally, 32% of Omvoh patients achieved early improvement in endoscopic response, defined by visible healing of the intestinal lining, versus 11% on placebo at three months.
Omvoh is also being studied in VIVID-2, an ongoing, open-label extension (OLE) study evaluating the eﬃcacy and safety of Omvoh for up to three years in adults with moderately to severely <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41580394/eli-lillys-mirikizumab-shows-long-term-sustained-efficacy-safety-for-ulcerative-colitis-and-crohn" rel="noreferrer noopener">active Crohn&#8217;s disease</a>.
Among patients who achieved endoscopic response at one year in VIVID-1, over 80% maintained endoscopic response with one year of additional treatment (two years of continuous treatment).
Additionally, among patients who achieved clinical remission and endoscopic response at one year in VIVID-1, nearly 90% maintained clinical remission with one year of additional treatment (two years of continuous treatment).
Price Action: LLY stock is down 0.29% at $755.40&nbsp;during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43039195/spruce-point-sees-trouble-ahead-for-procept-biorobotics" target="_blank" rel="noreferrer noopener">Spruce Point Sees Trouble Ahead For Procept BioRobotics</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease

Hims & Hers Health, Inc. Class A Common Stock

HIMS

U.S. FDA Chief Califf Says Current Regulations Not Enough To Protect Americans From Risks Of Compounded GLP-1 Drugs

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 52 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable options, 11 are puts, totaling $413,328, and 41 are calls, amounting to $2,523,494.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $1440.0 for Eli Lilly during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $250.0 to $1440.0 in the last 30 days. 
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737051361_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$501.75</td>
<td>$497.6</td>
<td>$500.09</td>
<td>$250.00</td>
<td>$250.0K</td>
<td align="right">61</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$21.8</td>
<td>$20.4</td>
<td>$20.45</td>
<td>$735.00</td>
<td>$153.3K</td>
<td align="right">123</td>
<td align="right">75</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$20.65</td>
<td>$20.6</td>
<td>$20.6</td>
<td>$780.00</td>
<td>$109.2K</td>
<td align="right">999</td>
<td align="right">65</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$71.3</td>
<td>$69.7</td>
<td>$71.0</td>
<td>$760.00</td>
<td>$106.5K</td>
<td align="right">112</td>
<td align="right">16</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$167.5</td>
<td>$163.05</td>
<td>$165.46</td>
<td>$590.00</td>
<td>$99.2K</td>
<td align="right">142</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>Trading volume stands at 1,491,322, with LLY's price up by 1.89%, positioned at $760.86.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 21 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Eli Lilly's Options: A Look at What the Big Money is Thinking

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 15 years by 10.74% on an annualized basis producing an average annual return of 22.68%. Currently, Eli Lilly has a market capitalization of $723.79 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 15 years ago, it would be worth $21,118.25 today based on a price of $762.43 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737045917_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today

Eli Lilly Announces The FDA Has Approved Omvoh For The Treatment Of Moderately To Severely Active Crohn's Disease in Adults

Just before the JP Morgan healthcare conference, Eli Lilly and Co&nbsp;(NYSE:&nbsp;LLY) announced that it expects 2024 full-year worldwide revenue to be approximately&nbsp;$45.0 billion, representing a 32% growth compared to the previous year versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42976923/eli-lilly-expects-around-55-billion-sales-from-weight-lossdiabetes-drugs-with-overall-topline-growth-of-32-issues-2025-forecast" rel="noreferrer noopener">consensus of $45.50 billion</a>.
The company's expected 2024 revenue is&nbsp;$400 million, or about 3%, below the guidance range issued during the&nbsp;third-quarter earnings. The guidance includes approximately&nbsp;$3.5 billion&nbsp;for Mounjaro and $1.9 billion&nbsp;for Zepbound.
During the conference, David Ricks outlined two reasons for the guidance update:
<ul>
<li>The diabetes GLP market, in December, outperforms the rest of the quarter and in year this did not happen&#8230;The CEO said this could be just a guess. The company said it did not predict it. "This year that didn't happen in GLP-1," said Ricks, who speculated that changes in Medicare Part D and insurance edits have prevented patients from doubling up their prescriptions at the end of the year to avoid deductible costs early in the following year."</li>
<li>Stocking levels were a big discussion during Q3 results. The company dropped about 8 selling days in that quarter alone. The company expected a buildback at the end of the year because every year, a couple of days of buildback happen, and it did not happen this year.</li>
</ul>
Regarding the guidance approach, the CEO noted, "The scale of this business and the way it's been growing, the consumer part of it, along with the stocking dynamics, it's just been a learning [experience] for us," Ricks said. "Our forecasters really nailed the rest of the portfolio. We don't have a problem with forecasting. It's just, this market is quite different."
Goldman analyst Chris Shibutani writes, "We expect this preliminary 4Q results to heighten concerns relating to underlying demand dynamics, which initially emerged at a broader level amongst investors during the 3Q results and guidance update."
Price Action: LLY stock is up 0.59% at $749.28 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/43004444/intel-plans-to-spin-off-5-billion-venture-capital-segment-will-remain-anchor-investor" target="_blank" rel="noreferrer noopener">Intel Plans To Spin Off $5 Billion Venture Capital Segment, Will Remain Anchor Investor</a></li>
</ul>
Photo via Eli Lilly and Company

Analyst Color

Guidance

Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall

The U.S. stock market experienced mixed results on Tuesday. The Dow Jones index climbed over 220 points to 42,518.28, while the Nasdaq saw a decline of 0.2% to 19,044.39. The S&amp;P 500 showed modest gains. rising 0.1% to 5,842.91.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
Microsoft&#8217;s stock dipped by 0.36%, closing at $415.67. The stock reached an intraday high of $419.74 and a low of $410.72, with a 52-week range between $384.81 and $468.35. The tech giant <a href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence">announced a new engineering organization</a>, CoreAI—Platform and Tools, aimed at enhancing its AI capabilities. This division will integrate various teams to develop the end-to-end Copilot and AI stack, including GitHub Copilot.
Applied Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>).
Applied Digital&#8217;s shares surged 9.98%, closing at $8.54. The stock hit an intraday high of $9.72 and a low of $8.25, with a 52-week range from $2.36 to $11.25. The company reported impressive fiscal second-quarter results, with revenue of $63.9 million, surpassing analyst expectations. The growth was largely driven by its&nbsp;<a href="https://www.benzinga.com/news/earnings/25/01/42990272/applied-digital-q2-earnings-revenue-beat-eps-beat-cloud-services-growth-late-stage-discussions-with-multiple-hyperscalers-and-more">Cloud Services</a>&nbsp;sector, which saw a 523% increase year-over-year.
Rigetti Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)
Rigetti Computing&#8217;s stock skyrocketed 47.93%, closing at $8.95. It reached an intraday high of $8.97 and a low of $6.56, with a 52-week range of $0.66 to $21.42. The <a href="https://www.benzinga.com/news/25/01/42978003/whats-going-on-with-rigetti-computing-rgti-stock-4">stock rebounded</a> after previous declines, following remarks by Nvidia and Meta executives about the timeline for quantum computing. Despite the uncertainty, Rigetti&#8217;s shares saw a significant boost, reflecting investor optimism in its potential.
Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)
Eli Lilly&#8217;s shares fell 6.59%, closing at $744.91. The stock had an intraday high of $784.23 and a low of $729, with a 52-week range of $612.7 to $972.53. The company reduced its fourth-quarter revenue guidance, expecting $13.5 billion, below previous estimates. Despite this, Eli Lilly anticipates strong sales from its&nbsp;<a href="https://www.benzinga.com/25/01/42976923/eli-lilly-expects-around-55-billion-sales-from-weight-lossdiabetes-drugs-with-overall-topline-growth-of-32-issues-2025-forecast">weight loss and diabetes drugs</a>.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla&#8217;s stock decreased by 1.72%, closing at $396.36. It reached an intraday high of $422.64 and a low of $394.54, with a 52-week range from $138.80 to $488.54. The company saw a rise in Cybertruck sales, with nearly 39,000 units sold in 2024. However, this success came at the expense of its luxury Model S and X sales, which saw significant declines. The data highlights the impact of the <a href="https://www.benzinga.com/25/01/42967593/cybertruck-sales-rise-in-2024-weighed-down-on-tesla-model-s-deliveries-in-us-shows-data">Cybertruck&#8217;s popularity</a> on Tesla&#8217;s overall sales strategy.
Prepare for the day&#8217;s trading <a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a> by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42978783/xpeng-teams-up-with-bp-pulse-to-expand-ev-charging-network-across-china-report">XPeng Teams Up With BP Pulse To Expand EV Charging Network Across China: Report</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

APLD

MSFT

RGTI

Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Editor&#8217;s note: This story has been updated to correct the spelling of Eli Lilly in the headline. 
A cooler-than-expected December producer inflation report failed to ignite lasting gains on Wall Street Tuesday, reflecting lingering concerns about persistently high inflation <a href="https://www.benzinga.com/topic/inflation">among investors</a>.
Early session advances across major indices faded into modest losses by midday trading in New York, as market participants exercised caution ahead of Wednesday's pivotal Consumer Price Index report and key fourth-quarter earnings from top Wall Street banks.
The Producer Price Index rose 3.3% year-over-year in December, accelerating from November's 3% increase but missing the 3.4% forecast. On a monthly basis, producer prices climbed 0.2%, slowing from November's 0.4% rise and falling short of the 0.3% <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42974739/wall-street-rebounds-as-producer-inflation-misses-estimates-tesla-gains-chinese-stocks-rally">consensus estimate</a>.
Core PPI, which excludes volatile food and energy prices, increased 3.5% annually, matching November's pace but undershooting expectations of 3.8%. On a month-to-month basis, core inflation stagnated, showing zero growth compared to November's 0.2% increase, and coming in below forecasts for a 0.3% gain.
Bond yields continued to climb, underscoring persistent inflationary pressure. The 30-year Treasury yield advanced to 5%, its highest level since October 2023 and marking territory not seen since August 2007.
After a three-day rally, crude oil prices cooled. West Texas Intermediate fell 1% to $78 per barrel, as investors locked in recent gains.
Utilities and financials emerged as the session's strongest performers, while healthcare stocks were the largest drag on the market. Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) plummeted 7.5% after the company issued a weaker-than-expected fourth-quarter sales forecast for its weight-loss drug Zepbound.
Peer Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) slid 5% in sympathy.
CEO Dave Ricks revealed that Eli Lilly anticipates regulatory approval for its oral weight-loss treatment, orforglipron, by 2026, with pivotal data expected in mid-2025. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.5% on Tuesday, bouncing back after three days of largely flat trading.
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,194.61</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,241.81</td>
<td>-0.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,818.04</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,704.24</td>
<td>-0.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) eased 0.4% to $579.14.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.2% down to $422.07.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.6% to $502.89.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.1% higher to $217.45.</li>
<li>The&nbsp;Utilities Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 0.8%; the&nbsp;Health Care Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 1.8%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
<ul>
<li>Chinese stocks rallied amid regulatory reassurance on markets. Shares of JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) rose 4.6%, followed by gains in Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), up 2.5% and 2.2%, respectively. </li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell over 3% after announcing on Tuesday that it delivered 57 commercial aircraft in the fourth quarter of 2024, a sharp decline from 116 deliveries in the previous quarter. </li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/42965857/oil-could-hit-90-goldman-sachs-says-trump-may-not-ease-sanctions-on-russia">Oil Could Hit $90, Goldman Sachs Says: &#8216;Trump May Not Ease Sanctions&#8217; On Russia</a></li>
</ul>
Photo via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Movers

ETFs

$BTC

BIDU

SPDR Dow Jones Industrial Average ETF Trust

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Eli Lilly Tumbles: What's Driving Markets Tuesday? (CORRECTED)

On Tuesday, Eli Lilly and Co (NYSE:&nbsp;LLY) announced that it expects 2024 full-year worldwide revenue to be approximately&nbsp;$45.0 billion, representing a 32% growth compared to the previous year versus the <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">consensus of $45.50 billion</a>.
Eli Lilly expects fourth-quarter 2024 revenue of approximately&nbsp;$13.5 billion, representing a 45% year-over-year growth compared to the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42973698/lilly-provides-update-on-2024-revenue-guidance-announces-2025-revenue-guidance" rel="noreferrer noopener">consensus of $13.97 billion</a>.
The company&#8217;s expected 2024 revenue is&nbsp;$400 million, or about 3%, below the guidance range issued during the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">third-quarter earnings</a>. The guidance includes approximately&nbsp;$3.5 billion&nbsp;for Mounjaro and $1.9 billion&nbsp;for Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion" rel="noreferrer noopener">Eli Lilly Scoops Up Scorpion Therapeutics&#8217; Early-Stage Cancer Program For $2.5 Billion</a>
In addition to the uptake of Mounjaro and Zepbound, Lilly saw a strong performance in its oncology, immunology, and neuroscience medicines in the fourth quarter. In total,&nbsp;non-incretin revenue grew by 20% year-over-year.
&#8220;While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration of growth for the quarter. That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results. We continued to make progress on our manufacturing build-out, and U.S. supply across all doses of tirzepatide was available throughout Q4,&#8221; said&nbsp;David Ricks, Lilly chair and CEO. &#8220;The rest of our medicines performed within our expectations.&#8221;&nbsp;
&#8220;We&#8217;ll also bring additional manufacturing capacity online and expect to produce at least 60% more salable doses of incretins in the first half of the year compared to the first half of 2024,&#8221; Ricks added.
The company also shared 2025 revenue guidance, anticipating sales between&nbsp;$58.0 billion&nbsp;and&nbsp;$61.0 billion compared to the consensus of $58.6 billion.
Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca, Ebglyss, Omvoh&nbsp;and Kisunla; approvals of new indications for existing Lilly medicines; launches of Mounjaro in additional worldwide markets, as well as potential launches of new medicines such as imlunestrant for metastatic breast cancer. Incretin market and channel dynamics have been factored into the 2025 revenue guidance range.
Price Action: LLY stock is down 8.03% at $775.10&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/42974632/us-listed-chinese-stocks-rally-on-strong-trade-data-central-bank-support-goldman-forecasts-20-growth" target="_blank" rel="noreferrer noopener">US Listed Chinese Stocks Rally on Strong Trade Data, Central Bank Support, Goldman Forecasts 20% Growth</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Earnings

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks

WIIM

Eli Lily shares are trading lower after the company issued FY24 revenue guidance below the previous estimate.

Eli Lilly Expects 2024 Revenue of $45.0B, About 3% Below Guidance Range Issued On Oct. 30; Issues 2025 Guidance of $58.0B-$61.0B

<a href="https://www.bloomberg.com/news/articles/2025-01-13/lilly-asks-biden-administration-to-pause-drug-price-negotiations?srnd=homepage-europe">https://www.bloomberg.com/news/articles/2025-01-13/lilly-asks-biden-administration-to-pause-drug-price-negotiations?srnd=homepage-europe</a>
&nbsp;
Drugmaker Eli Lilly &amp; Co. has asked the US government to pause its forward march with drug-price negotiations, potentially thwarting the Biden administration's plans to release a new list of drug targets before leaving office next week.&nbsp;

Politics

'Lilly Asks Biden Administration to Pause Drug-Price Negotiations' - Bloomberg News

<a href="https://www.bloomberg.com/news/articles/2025-01-13/lilly-sees-new-weight-loss-pill-approval-in-early-2026-ceo-says?srnd=homepage-europe">https://www.bloomberg.com/news/articles/2025-01-13/lilly-sees-new-weight-loss-pill-approval-in-early-2026-ceo-says?srnd=homepage-europe</a>
&nbsp;
Eli Lilly &amp; Co. is projecting approval of its experimental weight-loss pill as soon as early 2026, Chief Executive Officer Dave Ricks said, one of several in a new generation of the popular drugs.&nbsp;

'Lilly Sees New Weight-Loss Pill Approval in Early 2026, CEO Says' - Bloomberg News

On Monday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) agreed to acquire Scorpion Therapeutics, Inc&#8217;s PI3Kα inhibitor <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42945183/lilly-to-acquire-scorpion-therapeutics-mutant-selective-pi3k-inhibitor-program" rel="noreferrer noopener">program STX-478</a>.
STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.&nbsp;
Additionally, as part of the transaction, the privately-held Scorpion will spin out a new entity to hold its employees and non-PI3Kα&nbsp;pipeline assets.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42901177/obesity-treatments-ma-activity-to-take-center-stage-during-upcoming-jpm-healthcare-conference" rel="noreferrer noopener">Obesity Treatments, M&amp;A Activity To Take Center Stage During Upcoming JPM Healthcare Conference</a>
The new, independent company would be owned by Scorpion&#8217;s current shareholders, with Lilly holding a minority equity interest.
The new company will be led by members of the current Scorpion management team.
The Financial Times report <a target="_blank" href="https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2" rel="noreferrer noopener">added</a> the proposed deal is a part of Eli Lilly&#8217;s strategy to reinvest profits from its successful diabetes and obesity drugs, Mounjaro and Zepbound, into expanding its drug pipeline.
Under the terms of the agreement, Lilly will acquire Scorpion, and Scorpion shareholders could receive up to $2.5 billion in cash. Up to $1 billion will be paid upfront, with an additional $1.5 billion contingent on meeting specific performance milestones.
Price Action: Eli Lilly stock is down 1.55% at $787.49 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42946734/why-is-depression-focused-sage-therapeutics-stock-surging-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?</a></li>
</ul>
Image: Shutterstock

Asset Sales

Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial
STX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly's advancements against this disease

Eli Lilly To Acquire Scorpion Therapeutics' Nutant-selective PI3Kα Inhibitor Program; Scorpion Shareholders Could Receive Up To $2.5M In Cash

<a href="https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2" title="https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2">https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2</a>

"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times

Alchemab's technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience.&nbsp;
&nbsp;

Contracts

On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To Receive Milestone Payments, Plus Royalties

Finally An Attractive Entry Point Into Novo Nordisk

Least shorted S&P 500 stocks in December

Guggenheim lowered the firm's price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its glob...

Eli Lilly price target lowered to $973 from $995 at Guggenheim

Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial

Novo Nordisk ($NVO) stock fell as its blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are lined up for Medicare price negotiatio...

Novo Nordisk's (NYSE:NVO) Ozempic and Wegovy Lined Up for Medicare Drug Price Negotiations

Argus lowered the firm's price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the stock's "d...

Novo Nordisk price target lowered to $110 from $140 at Argus

BofA spotlights four bulls and two bears: LLY, TGT, PYPL, MCK, AR, and EWBC

Hims & Hers Health down 3% after BoA says Q4 revenue could be a miss

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon

ABCL

AMZN

CGON

EWBC

GILD

GOOG

GOOGL

ILMN

ITCI

MLTX

NONOF

NVSEF

PYPL

REGN

RHHBY

RHHVF

RLAY

SCHW

SLRN

TCHBF

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

Opinion

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

Lilly to participate in J.P. Morgan Healthcare Conference

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Comments

Eli Lilly

ニュース

最新ニュース Eli Lilly (NYSE:LLY) 株価情報

月曜日, 8 12, 2024

金曜日, 7 26, 2024

水曜日, 6 19, 2024

火曜日, 5 07, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル